WO2024056044 - GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY-CHAIN ANTIBODIES

National phase entry:
Publication Number WO/2024/056044
Publication Date 21.03.2024
International Application No. PCT/CN2023/118958
International Filing Date 15.09.2023
Title **
[English] GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY-CHAIN ANTIBODIES
[French] ANIMAUX NON HUMAINS GÉNÉTIQUEMENT MODIFIÉS ET PROCÉDÉS DE PRODUCTION D'ANTICORPS À CHAÎNE LOURDE
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
HU, Yiqing
ZHANG, Qi
ZHANG, Lijun
ZHANG, Yabo
ZHAO, Huizhen
YAO, Jiawei
SHEN, Yuelei
Priority Data
PCT/CN2022/119188   16.09.2022   CN
PCT/CN2022/136246   02.12.2022   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting4778
EPO Filing, Examination, Granting77889
Japan Filing, Examination, Granting4368
South Korea Filing, Examination, Granting6677
USA Filing, Examination, Granting31240
MasterCard Visa
Total: 124,952

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The present disclosure relates to genetically modified animals and methods for producing heavy-chain antibodies. In one aspect, the genetically modified non-human animal comprises a modified immunoglobulin heavy chain locus, wherein the modified immunoglobulin heavy chain locus comprises an IgG constant region gene, wherein the IgG constant region gene encodes an IgG heavy chain constant region lacking a CH1 domain, wherein the genetically modified non-human animal expresses a heavy-chain antibody. Also disclosed herein are anti-TFR1 antibodies, antigen-binding fragments, and the uses thereof.[French] La présente invention concerne des animaux génétiquement modifiés et des procédés de production d'anticorps à chaîne lourde. Selon un aspect, l'animal non humain génétiquement modifié comprend un locus de chaîne lourde d'immunoglobuline modifiée, le locus de chaîne lourde d'immunoglobuline modifiée comprenant un gène de région constante d'IgG, le gène de région constante d'IgG codant pour une région constante de chaîne lourde d'IgG dépourvue de domaine CH1, l'animal non humain génétiquement modifié exprimant un anticorps à chaîne lourde. L'invention concerne également des anticorps anti-TFR1, des fragments de liaison à l'antigène et leurs utilisations.

Rejoining the server...